Pathway components included stabilized p53 (p-p53S15), p21CIP (CDKN1A), mitogen-activated protein kinase (extracellular signal-regulated kinases 1 and 2 (ERK1/2), p38 kinase), AKT signaling as well as checkpoint-kinase 1 (CHK1), a direct target of ataxia telangiectasia mutated and ataxia telangiectasia and RAD3-related signaling. The gene discussed is MAPK3; the disease is Telangiectasia.